Global Respiratory Drugs Pipeline Analysis Market 2018

April 2018 | 188 pages | ID: G38C182A4EFEN
IHR Insights

Abstracts

Respiratory Drugs Pipeline Analysis

Overview: Pulmonary medicine is the branch of medical science that deals with diagnosis, prevention, and treatment of diseases affecting the respiratory system. Respiratory drugs finds its applications in Asthma, COPD, Cystic Fibrosis, Allergic Rhinitis and Others. Asthma is the major market share holder currently. The intensity of competition in the respiratory drug market is high with few players dominating the market. The high investments made in the development of respiratory drug delivery systems have favored the growth of the market. The entry of innovative and effective drugs in the market is expected to drive the future of the market.

Short-Acting Beta2-Agonists (SABA), Inhaled corticosteroids (ICS), anticholinergics, long-acting beta2-agonists (LABA), antihistamines, vasodilators, combination drugs, and others are the major respiratory dugs classes available in the market. Currently, primarily combination drugs drive the market, with top brands facing no real competition from generic alternatives. The emergence of inexpensive, state-of-the-art and effective drug delivery devices will provide stimulate the market growth.

Industry Trends

• GSK’s Adavir for Asthma and COPD remains as the top selling drug in the market, even on declined revenue in 2017
• Pharmaceutical companies in US are facing pricing pressure and launch of new respiratory drugs in the market are declining the sales of the blockbuster drugs in the market
• Cipla Ltd., a leader in the Indian market, announced in May 2017, that it planned to reduce the investment on the biosimilars, to increase their focus on the respiratory drugs due to the high profitability

More than 30 companies pipeline for the respiratory drugs is analyzed in the study. GlaxoSmithKline plc has the highest number of pipeline molecules in various clinical trials phases.

Benefits: The report provides complete details about the usage and adoption rate of respiratory drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Contents

1 INDUSTRY OUTLOOK

1.1 Industry Overview
  1.1.1 Global Driver for Pharmaceutical Demand:
  1.1.2 Pharmaceutical spending region wise
  1.1.3 R&D pipeline in pharmaceutical industry
  1.1.4 Top pharma drugs by sales in 2017 ($Million)
1.2 Industry Trends
1.3 Pest Analysis

2 REPORT OUTLINE

2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 MARKET SNAPSHOT

3.1 Market Definition – Infoholic Research
3.2 Segment Addressable Market
3.1 Trends of Respiratory Drugs Market

4 MOLECULE TYPE: ANALYSIS

4.1 Overview

5 APPLICATION: ANALYSIS

5.1 Overview
5.2 Asthma
  5.2.1 Key Takeaways
  5.2.2 Company Analysis
5.3 Chronic Obstructive Pulmonary Disease (COPD)
  5.3.1 Key Takeaways
  5.3.2 Company Analysis
5.4 Cystic Fibrosis
  5.4.1 Key Takeaways
  5.4.2 Company Analysis
5.5 Lung Cancer
  5.5.1 Key Takeaways
  5.5.2 Company Analysis
5.6 Nasal Polyps
  5.6.1 Key Takeaways
5.7 Idiopathic Pulmonary Fibrosis
  5.7.1 Key Takeaways
  5.7.2 Company Analysis
5.8 Others

6 COMPETITIVE LANDSCAPE

  6.1.1 Company Analysis

7 VENDORS PROFILE

7.1 AbbVie Inc
  7.1.1 Overview
  7.1.2 Geographic Presence
  7.1.3 Business Focus
  7.1.4 SWOT Analysis
  7.1.5 Business Strategies
7.2 Amgen Inc
  7.2.1 Overview
  7.2.2 Geographic Presence
  7.2.3 Business Focus
  7.2.4 SWOT Analysis
  7.2.5 Business Strategies
7.3 Astra Zeneca PLC
  7.3.1 Overview
  7.3.2 Geographic Presence
  7.3.3 Business Focus
  7.3.4 SWOT Analysis
  7.3.5 Business Strategy
7.4 Bayer AG
  7.4.1 Overview
  7.4.2 Business Unit
  7.4.3 Geographic Presence
  7.4.4 Business Focus
  7.4.5 SWOT Analysis
  7.4.6 Business Strategy
7.5 Boehringer Ingelheim GmbH
  7.5.1 Overview
  7.5.2 Geographic Presence
  7.5.3 Business Focus
  7.5.4 SWOT Analysis
  7.5.5 Business Strategy
7.6 Bristol-Myers Squibb
  7.6.1 Overview
  7.6.2 Geographic Presence
  7.6.3 Business Focus
  7.6.4 SWOT Analysis
  7.6.5 Business Strategy
7.7 Celgene Corporation
  7.7.1 Overview
  7.7.2 Geographic Presence
  7.7.3 Business Focus
  7.7.4 SWOT Analysis
  7.7.5 Business Strategy
7.8 Dr .Reddy’s Laboratories Limited
  7.8.1 Overview
  7.8.2 Business Unit
  7.8.3 Geographic Presence
  7.8.4 Business Focus
  7.8.5 SWOT Analysis
  7.8.6 Business Strategy
7.9 Eli Lilly & Company Ltd
  7.9.1 Overview
  7.9.2 Business Focus
  7.9.3 SWOT Analysis
  7.9.4 Business Strategies
7.10 F.Hoffmann-La Roche Ltd
  7.10.1 Overview
  7.10.2 Business Unit
  7.10.3 Geographic Presence
  7.10.4 Business Focus
  7.10.5 SWOT Analysis
  7.10.6 Business Strategy
7.11 GlaxoSmithKline plc
  7.11.1 Overview
  7.11.2 Geographic Presence
  7.11.3 Business Focus
  7.11.4 SWOT Analysis
  7.11.5 Business Strategy
7.12 Johnson & Johnson
  7.12.1 Overview
  7.12.2 Business Units
  7.12.3 Geographic Revenue
  7.12.4 Business Focus
  7.12.5 SWOT Analysis
  7.12.6 Business Strategies
7.13 Merck & Co., Inc
  7.13.1 Overview
  7.13.2 Business units
  7.13.3 Geographic Revenue
  7.13.4 Business focus
  7.13.5 SWOT analysis
  7.13.6 Business strategies
7.14 Mylan N.V
  7.14.1 Overview
  7.14.2 Geographic Presence
  7.14.3 Business Focus
  7.14.4 SWOT Analysis
  7.14.5 Business Strategy
7.15 Novartis AG
  7.15.1 Overview
  7.15.2 Business Unit
  7.15.3 Geographic Presence
  7.15.4 Business Focus
  7.15.5 SWOT Analysis
  7.15.6 Business Strategy
7.16 Pfizer, Inc.,
  7.16.1 Overview
  7.16.2 Business Units
  7.16.3 Geographic Presence
  7.16.4 Business Focus
  7.16.5 SWOT Analysis
  7.16.6 Business Strategies
7.17 Sanofi
  7.17.1 Overview
  7.17.2 Geographic Presence
  7.17.3 Business Focus
  7.17.4 SWOT Analysis
  7.17.5 Business Strategy
7.18 Teva Pharmaceutical Industries Ltd
  7.18.1 Overview
  7.18.2 Business Unit
  7.18.3 Geographic Presence
  7.18.4 Business focus
  7.18.5 SWOT analysis
  7.18.6 Business Strategy
7.19 Vertex Pharmaceuticals Inc
  7.19.1 Overview
  7.19.2 Geographic Presence
  7.19.3 Business Focus
  7.19.4 SWOT Analysis
  7.19.5 Business Strategy

8 COMPANIES TO WATCH FOR

8.1 FibroGen, Inc
  8.1.1 Overview
  8.1.2 Highlights
8.2 Gilead Sciences Inc
  8.2.1 Overview
  8.2.2 Highlights:
8.3 Glenmark Pharmaceutical Ltd
  8.3.1 Overview
8.4 Zia Labs
  8.4.1 Overview
  8.4.2 Zia Lab: Highlights
8.5 Vectura Group Plc
  8.5.1 Overview
  8.5.2 Vectura Group Plc: Highlights
8.6 Sosei Group Corporation
  8.6.1 Overview
8.7 Almirall S.A
  8.7.1 Overview
8.8 Biogen Inc
  8.8.1 Overview
8.9 CHIESI Farmaceutici SpA
  8.9.1 Overview
  8.9.2 CHIESI Farmaceutici SpA: Highlights
8.10 Takeda Pharmaceutical Co, Ltd
  8.10.1 Overview
  8.10.2 Highlights
8.11 Shionogi & Co., Ltd
  8.11.1 Overview
  8.11.2 Shionogi & Co., Ltd: Highlights
8.12 Sun Pharmaceuticals
  8.12.1 Overview
  8.12.2 Highlights
8.13 United Therapeutics Corp
  8.13.1 Overview
  8.13.2 Highlights
8.14 ProMetic Life Sciences Inc
  8.14.1 Overview
  8.14.2 ProMetic Life Sciences Inc.: Highlights
8.15 Daiichi Sankyo, Inc
  8.15.1 Overview
  8.15.2 Overview
8.16 Aurobindo Pharma Ltd
  8.16.1 Overview
  8.16.2 Aurobindo Pharma Ltd: Highlights
8.17 Eisai Co., Ltd
  8.17.1 Overview
  8.17.2 Eisai Co., Ltd: Highlights
8.18 Shire Plc
  8.18.1 Overview
  8.18.2 Shire Plc: Highlights
8.19 GNI Group Ltd
  8.19.1 Overview
8.20 MediciNova, Inc
  8.20.1 Overview
8.21 Ono Pharmaceutical Co., Ltd
  8.21.1 Overview
8.22 Promedior, Inc
  8.22.1 Overview
8.23 Sumitomo Dainippon Pharma Co., Ltd
  8.23.1 Overview
  8.23.2 Sumitomo Dainippon Pharma Co., Ltd: Highlights

9 ANNEXURE

Abbreviations

List Of Tables

LIST OF TABLES

Table 1 MOLECULES IN PIPELINE FOR ASTHMA
Table 2 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER
Table 3 MOLECULES IN PIPELINE FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER
Table 4 MOLECULES IN PIPELINE FOR LUNG CANCER
Table 5 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS
Table 6 MOLECULES IN PIPELINE FOR IDOPATHIC PULMONARY FIBROSIS
Table 7 ABBVIE INC.: OFFERINGS
Table 8 ABBVIE INC: RECENT DEVELOPMENTS
Table 9 AMGEN INC.: OFFERINGS
Table 10 AMGEN INC.: RECENT DEVELOPMENTS
Table 11 ASTRA ZENCA PLC: OFFERINGS
Table 12 ASTRA ZENCA PLC: RECENT DEVELOPMENTS
Table 13 BAYER AG: OFFERINGS
Table 14 BAYER AG: RECENT DEVELOPMENTS
Table 15 BOEHRINGER INGELHEIM GMBH: OFFERINGS
Table 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS
Table 17 BRISTOL-MYERS SQUIBB: OFFERINGS
Table 18 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT
Table 19 CELGENE CORPORATION: OFFERINGS
Table 20 CELGENE CORPORATION: RECENT DEVELOPMENTS
Table 21 DR .REDDY’S LABORATORIES LIMITED: PRODUCT OFFERINGS
Table 22 DR .REDDY’S LABORATORIES LIMITED: RECENT DEVELOPMENTS
Table 23 ELI LILLY & COMPANY LTD.: PRODUCT OFFERINGS
Table 24 ELI LILLY & COMPANY LTD.: RECENT DEVELOPMENTS
Table 25 F .HOFFMANN-LA ROCHE LTD.: OFFERINGS
Table 26 F .HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS
Table 27 GLAXOSMITHKLINE PLC: OFFERINGS
Table 28 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 29 JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 30 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 31 MERCK & CO: PRODUCT OFFERINGS
Table 32 MERCK & CO: RECENT DEVELOPMENTS
Table 33 MYLAN N.V.: OFFERINGS
Table 34 MYLAN N.V.: RECENT DEVELOPMENT
Table 35 NOVARTIS AG: OFFERINGS
Table 36 NOVARTIS AG: RECENT DEVELOPMENTS
Table 37 PFIZER, INC.: OFFERINGS
Table 38 PFIZER, INC.: RECENT DEVELOPMENTS
Table 39 SANOFI: OFFERINGS
Table 40 SANOFI: RECENT DEVELOPMENTS
Table 41 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS
Table 42 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS
Table 43 VERTEX PHARMACEUTICALS INC.: OFFERINGS
Table 44 VERTEX PHARMACEUTICALS INC.: RECENT DEVELOPMENTS
Table 45 FIBROGEN, INC: OVERVIEW
Table 46 FIBROGEN INC: RECENT DEVELOPMENTS
Table 47 GILEAD SCIENCES INC.: OVERVIEW
Table 48 GILEAD SCIENCE INC: RECENT DEVELOPMENTS
Table 49 GLENMARK PHARMACEUTICAL LTD: OVERVIEW
Table 50 GLENMARK PHARMACEUTICAL LTD: RECENT DEVELOPMENTS
Table 51 ZIA LAB: OVERVIEW
Table 52 ZIA LAB: RECENT DEVELOPMENTS
Table 53 VECTURA GROUP PLC: OVERVIEW
Table 54 VECTURA GROUP AG: RECENT DEVELOPMENTS
Table 55 SOSEI GROUP CORPORATION: OVERVIEW
Table 56 SOSEI GROUP CORPORATION: RECENT DEVELOPMENTS
Table 57 ALMIRALL S.A: OVERVIEW
Table 58 ALMIRALL S.A.: RECENT DEVELOPMENTS
Table 59 BIOGEN INC: OVERVIEW
Table 60 BIOGEN INC: RECENT DEVELOPMENTS
Table 61 CHIESI FARMACEUTICI SPA: OVERVIEW
Table 62 CHIESI FARMACEUTICI SPA: RECENT DEVELOPMENTS
Table 63 TAKEDA PHARMACEUTICAL CO, LTD.: OVERVIEW
Table 64 TAKEDA PHARMACEUTICAL CO, LTD: RECENT DEVELOPMENTS
Table 65 SHIONOGI & CO., LTD: OVERVIEW
Table 66 SHIONOGI & CO., LTD: RECENT DEVELOPMENTS
Table 67 SUN PHARMACEUTICALS: OVERVIEW
Table 68 ZIA LAB: RECENT DEVELOPMENTS
Table 69 UNITED THERAPEUTICS CORP.: OVERVIEW
Table 70 PROMETIC LIFE SCIENCES INC.: OVERVIEW
Table 71 PROMETIC LIFE SCIENCES INC.: RECENT DEVELOPMENTS
Table 72 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS
Table 73 AUROBINDO PHARMA LTD: OVERVIEW
Table 74 AUROBINDO PHARMA LTD: RECENT DEVELOPMENTS
Table 75 EISAI CO., LTD: OVERVIEW
Table 76 EISAI CO., LTD: RECENT DEVELOPMENTS
Table 77 SHIRE PLC: OVERVIEW
Table 78 SHIRE PLC: RECENT DEVELOPMENTS
Table 79 GNI GROUP LTD: OVERVIEW
Table 80 GNI GROUP LTD: RECENT DEVELOPMENTS
Table 81 MEDICINOVA INC: OVERVIEW
Table 82 MEDICINOVA INC: RECENT DEVELOPMENTS
Table 83 ONO PHARMACEUTICAL CO., LTD: OVERVIEW
Table 84 ONO PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS
Table 85 PROMEDIOR, INC: OVERVIEW
Table 86 PROMEDIOR INC: RECENT DEVELOPMENTS
Table 87 SUMITOMO DAINIPPON PHARMA CO., LTD: OVERVIEW
Table 88 SUMITOMO DAINIPPON PHARMA CO., LTD: RECENT DEVELOPMENTS

List Of Charts

LIST OF CHARTS

Chart 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016)
Chart 2 PHARMACEUTICAL MOLECULLES IN DEVELOPMENT FOR NON-COMMUNICABLE DISEASES (NCDS)
Chart 3 R&D INVESTMENT BY TOP 10 COMPANIES ($BN)
Chart 4 PHARMACEUTICAL DRUGS BY SALES, 2017
Chart 5 PEST ANALYSIS OF RESPIRATORY DRUGS MARKET
Chart 6 RESEARCH METHODOLOGY OF RESPIRATORY DRUGS PIPELINE
Chart 7 NUMBER OF LARGE MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS
Chart 8 NUMBER OF SMALL MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS
Chart 9 RESPIRATORY PRODUCT PIPELINE BASED ON THE MOLECULE TYPE
Chart 1 RESPIRATORY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%)
Chart 2 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR ASTHMA
Chart 3 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER
Chart 4 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR CRONIC OBSTRUCTIVE PULMONARY DISORDER
Chart 5 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER
Chart 6 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR LUNG CANCER
Chart 7 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR IDOPATHIC PULMONARY FIBROSIS
Chart 8 NUMBER OF MOLECULES IN THE CLINICAL AND PRE-CLINICAL TRAILS FOR OTHER RESPIRATORY DISEASES
Chart 9 ABBVIEE INC: OVERVIEW SNAPSHOT
Chart 10 ABBVIEE INC.: GEOGRAPHIC PRESENCE
Chart 11 ABBVIE INC.: SWOT ANALYSIS
Chart 12 AMGEN INC.: OVERVIEW SNAPSHOT
Chart 13 AMGEN INC.: GEOGRAPHIC PRESENCE
Chart 14 AMGEN: SWOT ANALYSIS
Chart 15 ASTRA ZENCA PLC: OVERVIEW SNAPSHOT
Chart 16 ASTRA ZENCA PLC: BUSINESS UNITS
Chart 17 ASTRA ZENCA PLC: GEOGRAPHIC PRESENCE
Chart 18 ASTRA ZENCA PLC: SWOT ANALYSIS
Chart 19 BAYER AG: OVERVIEW SNAPSHOT
Chart 20 BAYER AG: BUSINESS UNITS
Chart 21 BAYER GA: GEOGRAPHICAL PRESENCE
Chart 22 BAYER AG: SWOT ANALYSIS
Chart 23 BOEHRINGER INGELHEIM GMBH: OVERVIEW SNAPSHOT
Chart 24 BOEHRINGER INGELHEIM GMBH: BUSINESS UNITS
Chart 25 BOEHRINGER INGELHEIM GMBH: GEOGRAPHIC PRESENCE
Chart 26 BOEHRINGER INGELHEIM GMBH: SWOT ANALYSIS
Chart 27 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT
Chart 28 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS
Chart 29 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE
Chart 30 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS
Chart 31 CELGENE CORPORATION: OVERVIEW SNAPSHOT
Chart 32 CELGENE CORPORATION: GEOGRAPHIC PRESENCE
Chart 33 CELGENE CORPORATION: SWOT ANALYSIS
Chart 34 DR .REDDY’S LABORATORY LIMITED: OVERVIEW SNAPSHOT
Chart 35 DR .REDDY’S LABORATORY LIMITED: BUSINESS UNITS
Chart 36 DR .REDDY’S LABORATORY LIMITED: GEOGRAPHICAL PRESENCE
Chart 37 DR .REDDY’S LABORATORY LIMITED: SWOT ANALYSIS
Chart 38 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT
Chart 39 ELI LILLY & COMPANY LTD.: OVERVIEW SNAPSHOT
Chart 40 ELI LILLY & COMPANY LTD.: GEOGRAPHIC REVENUE
Chart 41 ELI LILLY & COMPANY LTD.: SWOT ANALYSIS
Chart 42 F .HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT
Chart 43 F .HOFFMANN.LA ROCHE LTD.: BUSINESS UNITS
Chart 44 F .HOFFMANN-LA ROCHE: GEOGRAPHICAL PRESENCE
Chart 45 F .HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS
Chart 46 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT
Chart 47 GLAXOSMITHKLINE PLC: BUSINESS UNITS
Chart 48 GLAXOSMITHKLINE PLC: GEOGRAPHIC PRESENCE
Chart 49 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
Chart 50 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 51 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 52 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 53 JOHNSON & JOHNSON: SWOT ANALYSIS
Chart 54 MERCK & CO: OVERVIEW SNAPSHOT
Chart 55 MERCK & CO: BUSINESS UNITS
Chart 56 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 57 MERCK & CO: SWOT ANALYSIS
Chart 58 MYLAN N.V .OVERVIEW SNAPSHOT
Chart 59 MYLAN N.V.: BUSINESS SEGMENTS
Chart 60 MYLAN N.V.: GEOGRAPHIC PRESENCE
Chart 61 MYLAN N.V.: SWOT ANALYSIS
Chart 62 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 63 NOVARTIS AG: BUSINESS UNITS
Chart 64 NOVARTIS AG: GEOGRAPHICAL PRESENCE
Chart 65 NOVARTIS AG: SWOT ANALYSIS
Chart 66 PFIZER, INC.: OVERVIEW SNAPSHOT
Chart 67 PFIZER INC.: BUSINESS UNITS
Chart 68 PFIZER INC.: GEOGRAPHIC PRESENCE
Chart 69 PFIZER INC: SWOT ANALYSIS
Chart 70 SANOFI SA: OVERVIEW SNAPSHOT
Chart 71 SANOFI SA: SEGMENTATION
Chart 72 SANOFI SA: GEOGRAPHIC REVENUE
Chart 73 SANOFI SA: SWOT ANALYSIS
Chart 74 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT
Chart 75 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS
Chart 76 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL PRESENCE
Chart 77 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS
Chart 78 VERTEX PHARMACEUTICALS INC.: OVERVIEW SNAPSHOT
Chart 79 VERTEX PHARMACEUTICALS INC.: GEOGRAPHICAL PRESENCE
Chart 80 VERTEX PHARMACEUTICALS INC.: SWOT ANALYSIS